This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Makes Cigna (CI) a New Buy Stock
by Zacks Equity Research
Cigna (CI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Radian Group (RDN) Okays Share Buyback Program Worth $200M
by Zacks Equity Research
Radian Group's (RDN) new share repurchase program reflects effective capital deployment backed by solid financial position banking on strong core operations.
BioDelivery (BDSI) Earnings & Sales Beat Estimates in Q2
by Zacks Equity Research
BioDelivery (BDSI) reports earnings against expectations of loss in Q2 and raises guidance for 2019.
Assurant (AIZ) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Assurant (AIZ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Outlook for Health Insurance Industry Looks Sanguine
by Sapna Bagaria
Consolidation, increasing senior population, technological advancements and development of supplementary healthcare businesses poise the health insurance industry for secular growth.
Buy CVS Health (CVS) Ahead of Q2 Earnings?
by Christopher Vargas
CVS Health (CVS) will be reporting their second quarter before the opening bell on Wednesday.
Should Value Investors Buy Cigna (CI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cigna (CI) Beats on Q2 Earnings and Revenues, Guides Up
by Zacks Equity Research
Cigna's (CI) Q2 earnings gain from the acquisition of Express Scripts, completed in December 2018.
Cigna (CI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 15.28% and 2.96%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) Q2 earnings should reflect increase in revenues from growth across its segments and share buyback.
Analysts Estimate Cigna (CI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna Stock Gains Near 9% on Drug Rebate Proposal Pullback
by Zacks Equity Research
Cigna's (CI) Pharmacy Benefits management is poised to gain due to the pullback of the drug rebate proposal.
ETFs to Shine as Trump Tosses Drug Rebate Curb Plan
by Sweta Jaiswal, FRM
We study the impact of Trump's dropping of the proposed drug rebate rule on some health ETFs with exposure to pharmacy benefit managers and healthcare insurers.
Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
by Zacks Equity Research
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
Company News for Jul 12, 2019
by Zacks Equity Research
Companies in the news are: CI, DAL, BBBY and FAST
Health Insurers Rejoice on Pullback of Drug Rebate Plan
by Sapna Bagaria
After many regulatory disturbances and overhang of the drug rebate ban proposal, a repeal of it is a breather for health insurers.
Cigna (CI) Jumps: Stock Rises 9.2%
by Zacks Equity Research
Cigna (CI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
by Christopher Vargas
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
Assurant Unveils Property CAT Reinsurance Program for 2019
by Zacks Equity Research
Assurant's (AIZ) 2019 property catastrophe reinsurance program is likely to lower the financial exposure of the company by about $1.4 billion.
Assurant Rallies 23% Year to Date: What's Aiding the Stock?
by Zacks Equity Research
Assurant's (AIZ) operational excellence and growth initiatives help the stock retain bull run.
Is Cigna (CI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Centene (CNC) Acquires Additional Stake in Ribera Salud
by Zacks Equity Research
Centene (CNC) buys a surplus share in Ribera Salud to fortify its footprint in Europe.
Top Ranked Growth Stocks to Buy for July 5th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 5th
MetLife (MET) to Sell Hong Kong Unit to Streamline Business
by Zacks Equity Research
MetLife (MET) to divest its Hong Kong unit to FWD Insurance for focusing on its profitable businesses.
What Makes Cigna (CI) a New Buy Stock
by Zacks Equity Research
Cigna (CI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.